CYP cynata therapeutics limited

9.68%

17.0¢

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

First 21 Last

Share
Profile

Follow
truss20

1,020 Posts.

401

12/10/22

14:04

Post #: 64159328
Share

Originally posted by JB1975: ↑

I genuinely welcome your contrarian posts.

When you saw the DSMB announcement and remembers the MEND announcement it was like you were speaking for me and reminding the group. I do think some here misinterpreted the DSMB annoucement relating to MEND as being a sort of endorsement of trial design when it was not.

But DFU in my opinion will he harder to stuff up the trial design for than was MEND.

Yet on the MEND side issue, sepsis, ARDs and CAR-T remain legitimate areas in which good trial designs might test potential therapies that would have merit.

My concern with DFU is not trial design its how much shareholder value has been retained by Ross Macdonald in his capacity as the steward of shareholder value in commercial in confidence arrangements with TekCyte.

With respect to milestones - that get mentioned here - milestones that are not anticipated before being reached are of a different sort than those that are laid out as KPIs ahead of time.

I accept Dr Jolanta Airey's statement that this "is a key milestone, which enables continued enrollment as planned" but it sound's to me like Ross speak.

And Ross's name still appears at the end of the announcement as authorising as CEO and Managing Director and that to me is still bad news for the shares that that is the case.

When Silviu spoke of milestones in the other MSC company you are aware of he used "major milestones" as a sort of way to mitigate failure to completely deliver to expectations set - like that a BLA resubmission would be made by end of the quarter.

In my opinion, CYPs near term share price gains are likely dependent on what MSB does, because CYP isn't hardly doing anything. Unfortunately I don't think MSB is on a positive trajectory either - MSB has just successfully gone dark on delivery dates without being pulled up on it and those delivery dates if they'd been met would have made Ross's planning of GvHD trials easier in my opinion because the FDA responding to MSB would have removed some of the fog.

Yet fog remains.

Expand

Sigh. I guess I have to post this again as it clearly didn't sink in last time. @col69 FYI this is part of the DSMB's responsibilities:

https://www.australianclinicaltrials.gov.au/sites/default/files/content/For%20researchers/Data%20Safety%20Monitoring%20Boards_1.pdf

CYP Price at posting: 36.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

First 21 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	18813	2
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-21

Top Stories

Monash IVF shares cater 25% – Disaster or deep-value play?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News